KIORA PHARMACEUTICALS INC Stock Price, News & Analysis

Welcome to our dedicated page for KIORA PHARMACEUTICALS news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on KIORA PHARMACEUTICALS stock.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage biotechnology company developing small-molecule therapies for retinal disease. The KPRX news feed highlights company announcements on its development pipeline, clinical trial progress, strategic partnerships, and intellectual property related to its lead programs KIO-301 and KIO-104.

Recent news releases describe ongoing Phase 2 clinical trials for retinal diseases. The ABACUS-2 trial evaluates KIO-301, a molecular photoswitch being developed for vision restoration in patients with retinitis pigmentosa, with plans to expand into choroideremia and Stargardt disease. The KLARITY study investigates KIO-104, a non-steroidal, immuno-modulatory DHODH inhibitor, in patients with retinal inflammation and macular edema across several inflammatory retinal diseases, including posterior non-infectious uveitis and diabetic macular edema.

Investors following KPRX news can review quarterly financial updates, as Kiora reports research and development spending, collaboration credits, and cash position alongside clinical development updates. Press releases also cover collaboration agreements, such as the exclusive co-development and commercialization relationship with Théa Open Innovation for KIO-301 outside Asia and the option agreement with Senju Pharmaceutical for key Asian markets.

The news stream further includes information on new U.S. patents that expand protection for KIO-104 and the KIO-100 family of compounds, as well as Kiora’s participation in initiatives like the RARE-X Vision Consortium for rare ocular disorders. For those tracking the KPRX stock and the company’s retinal disease programs, this page aggregates Kiora’s official news, conference participation announcements, and other disclosures in one place.